863111-54-0

Basic information

• Product Name: tert-butyl 4-(4-chloro-3-(trifluoromethyl)phenyl)-4-hydroxypiperidine-1-carboxylate
• Synonyms: tert-butyl 4-(4-chloro-3-(trifluoromethyl)phenyl)-4-hydroxypiperidine-1-carboxylate
• CAS NO: 863111-54-0
• Molecular Weight: 379.807
• Mol File: 863111-54-0.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: tert-butyl 4-(4-chloro-3-(trifluoromethyl)phenyl)-4-hydroxypiperidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 4-(4-chloro-3-(trifluoromethyl)phenyl)-4-hydroxypiperidine-1-carboxylate(863111-54-0)
• EPA Substance Registry System: tert-butyl 4-(4-chloro-3-(trifluoromethyl)phenyl)-4-hydroxypiperidine-1-carboxylate(863111-54-0)

Safety Data

• Hazardous Substances Data: 863111-54-0(Hazardous Substances Data)

Upstream product

• 445-01-2 5-bromo-2-chlorobenzotrifluoride 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 

Downstream Products

• 1266656-45-4 1-(5,5-bis(4-fluorophenyl)pentyl)-4-(4-chloro-3-(trifluoromethyl)phenyl)piperidin-4-ol 
• 1266656-50-1 4-(4-chloro-3-(trifluoromethyl)phenyl)-1-(4,4-diphenylbutyl)piperidin-4-ol 
• 863111-32-4 4-[4-chloro-3-(trifluoromethyl)phenyl]-4-fluoropiperidine 
• 21928-50-7 4-[4-chloro-3-trifluoromethylphenyl]-4-piperidinol 

Relevant articles and documents

Structure-Based Design and Synthesis of Piperidinol-Containing Molecules as New Mycobacterium abscessus Inhibitors

Non-tuberculous mycobacterium (NTM) infections, such as those caused by Mycobacterium abscessus, are increasing globally. Due to their intrinsic drug resistance, M. abscessus pulmonary infections are often difficult to cure using standard chemotherapy. We previously demonstrated that a piperidinol derivative, named PIPD1, is an efficient molecule both against M. abscessus and Mycobacterium tuberculosis, the agent of tuberculosis, by targeting the mycolic acid transporter MmpL3. These results prompted us to design and synthesize a series of piperidinol derivatives and to determine the biological activity against M. abscessus. Structure-activity relationship (SAR) studies pointed toward specific sites on the scaffold that can tolerate slight modifications. Overall, these results identified FMD-88 as a new promising active analogue against M. abscessus. Also, we determined the pharmacokinetics properties of PIPD1 and showed that intraperitoneal administration of this compound resulted in promising serum concentration and an elimination half-life of 3.2 hours.

DIPHENYLBUTYPIPERIDINE AUTOPHAGY INDUCERS

Autophagy inducing compounds, methods of their preparation and use, and kits containg said compounds are disclosed herein.

NEW SUBSTITUTED PIPERIDINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION

The present invention relates to compounds having therapeutic effects against disorders in the central nervous system, and in particular substituted hydroxypiperidines of the formula 1: wherein R1, R2, and R3 are as defined herein.